Jefferies & Co.

Jefferies & Co. is out with a research report on Wal-Mart (NYSE: WMT) and it has a Hold rating and is lowering its price target to $54 from $57 after it reported earnings. In a note to clients, Jefferies & Co. writes, "Share weakness reflects shaken confidence that better comp store sales...

Jefferies & Co. is out with a research report on Anadarko (NYSE: APC) and it has a Buy rating and a $104 price target on shares. In a note to clients, Jefferies & Co. writes, "Anticipated Niobrara update is very positive as APC may position for a joint venture. We believe APC could raise $...

Jefferies & Co. is out with a research report on Susser Holdings (NASDAQ: SUSS) and it is raising its price target to $30 from $26, but is keeping its Buy rating on shares. In a note to clients, Jefferies & Co. writes, "While an encore in fuel in 2012 looks less likely given the record...

Jefferies & Co. is out with a research report on Questcor Pharmaceuticals (NASDAQ: QCOR) and it is raising its price target to $50 from $44, and it has a Buy rating on shares. In a note to clients, Jefferies & Co. writes, "After attending the American Society of Nephrology meeting, we...

Jefferies & Co. is out with a research report on Globe Specialty Metals (NYSE: GSM) and it is lowering its price target to $22.50 from $25, and it has a Buy rating on shares. In a note to clients, Jefferies & Co. writes, "Following F1Q12 results, we have trimmed estimates and our target...

Jefferies & Co. is out with a research report on Broadsoft, Inc. (NASDAQ: BSFT) and it is raising its price target to $42 from $32, and it has a Buy rating on shares. In a note to clients, Jefferies & Co. writes, "We're increasing 2011 and 2012 sales expectations upward from $129.5 million...

Jefferies & Co. is out with a research report on Tekelec (NASDAQ: TKLC) and it is raising its price target to $11 from $7, and it has a Hold rating on shares. In a note to clients, Jefferies & Co. writes, "Tekelec announced today that it will be required by a consortium of private equity...

Jefferies & Co. is out with a research report on Altera Corp (NASDAQ: ALTR) and it is raising its price target to $46 from $43, and it has a Buy rating on shares. In a note to clients, Jefferies & Co. writes, "At its Nov 7th Analyst Day, ALTR management upped its long term business model...

Jefferies & Co. is out with a research report on Cisco (NASDAQ: CSCO) and it has a Hold rating and a $15.75 price target on shares. In a note to clients, Jefferies writes, "We expect Cisco to print fiscal Q1 results that are largely in line with prior guidance. Moreover, the guidance should be...

Jefferies & Co. is out with a research report on Health Care REIT (NYSE: HCN) and it is raising its price target to $52 from $48, and it has a Hold rating on shares. In a note to clients, Jefferies & Co. writes, "While we believe HCN is well-positioned to grow FFO/sh by 10%+ in 2012, we...

Jefferies & Co. is out with a research report on Chesapeake Energy (NYSE: CHK) and it is lowering its price target to $40 from $43, but it has a Buy rating on shares. In a note to clients, Jefferies & Co. writes, "CHK has an industry-leading portfolio of assets. Early indications are that...

Jefferies & Co. is out with a research report on AMAG Pharmaceuticals (NASDAQ: AMAG) and it has an Underperform rating and a $12 price target on shares. In a note to clients, Jefferies & Co. writes, "Management changes and expense alignment (vs. slow Feraheme sales) are positive. However,...

Jefferies & Co. is out with a research report on Savient Pharma (NASDAQ: SVNT) and it is lowering its price target to $2 from $3, but is keeping its Hold rating on shares. In a note to clients, Jefferies & Co. writes, "Narrower 3Q11 net loss of ~$27M (vs. our net loss estimate of ~$32M) on...

Jefferies & Co. is out with a research report on hhgregg, Inc. (NYSE: HGG) and it is raising its price target to $14 from $12, but is keeping its Hold rating. In a note to clients, Jefferies & Co. writes, "A lot of upside in sales for Q2 was driven by promotion and appeared to be without...

Jefferies & Co. is out with a research report on Teva Pharmaceutical (NASDAQ: TEVA) and it is lowering its price target to $43 from $59, and it has a Hold rating on shares. In a note to clients, Jefferies & Co. writes, "Despite using a $135M 1x gain to "beat" EPS, Teva's Q3 showed hope the...